Global
Global Home
|
CSL Behring US
|
CSL Plasma
|
All CSL Behring Web Sites
Include All CSL Behring Country Sites
Choose country
Australia
Austria
Belgium/Luxembourg
Brazil
Canada
China
Denmark
France
Germany
Italy
Japan
Mexico
Netherlands
Nordic
Spain
Switzerland
UK
USA
CSL Plasma US
CSL Plasma Germany
Home
About CSL Behring
Products
Patient Commitment
Quality & Safety
CSL Research & Development
Clinical Trials
Other Areas of Business
News Room
Knowledge Center
Careers
Home
> Home
Product Overview
CSL Behring develops, manufactures and markets protein based therapies, including:
Bleeding Disorders Therapies
Fluid Replacement Therapies
Hereditary Angioedema (HAE) Therapies
Immunoglobulin Therapies
Pulmonary Therapies
Wound Healing Therapies
Global Product Portfolio
Features
Policy Impact-Europe Winter 2013
Synergy Exists Amongst Public Policies in Europe and US
Personal Stories
Teenager Advocates for People Who Are Living with PI
Policy Impact-US Winter 2013
Public Policy Issues in US that Impact Access to Care
Corporate Responsibility Report
CSL sustains the community as well as the business
News
04-Jun-2013
CSL Behring Doses First Patient in Pivotal rVIII-SingleChain ...
30-Apr-2013
Kcentra™ Approved by FDA for Urgent Warfarin Reversal
16-Apr-2013
Berinert® Wins EMA Approval for Short-Term Prophy Label
04-Apr-2013
Privigen® Gains Approval for CIDP in Europe
03-Apr-2013
CSL Behring Continues to Donate Factor Product to WFH GAP Program
View all news
